EPA (high-dose ethyl ester) — The Cardiovascular Risk Reducer
EPA (high-dose ethyl ester), commonly known as icosapent ethyl, is a highly purified omega-3 fatty acid derivative. It is clinically proven to significantly reduce the risk of major adverse cardiovascular events in high-risk patients, making it a critical intervention for cardiovascular longevity.
Mechanism of Action
Icosapent ethyl is a highly purified and stable eicosapentaenoic acid (EPA) ethyl ester. Once ingested, it is de-esterified in the gut to release active EPA, which is absorbed into the bloodstream. EPA incorporates into cell membranes and atherosclerotic plaques, potentially exerting membrane-stabilizing, anti-inflammatory, and antioxidative effects. It may also have antithrombotic properties and contribute to the stabilization or regression of coronary plaque, independent of its triglyceride-lowering effects.
Human Trial Evidence
The REDUCE-IT trial (2019, NEJM) demonstrated that 4 g/day of icosapent ethyl reduced the risk of major adverse cardiovascular events by 25% in statin-treated patients with elevated triglycerides. The JELIS trial (2007, Lancet) also showed a 19% reduction in major coronary events with 1.8 g/day of EPA plus statin therapy compared to statin therapy alone in a Japanese population.
Dosing Protocol
2 g twice daily with food (total daily dose, 4 g) is the established dose in the REDUCE-IT trial. Prescription required (e.g., Vascepa).
Safety & Contraindications
Generally well-tolerated, but associated with a modestly increased risk of bleeding events and a significantly higher rate of hospitalization for atrial fibrillation or flutter. Prescription required. Contraindicated in patients with known hypersensitivity to fish or shellfish. Use with caution in patients on anticoagulants or antiplatelet agents.